Welcome To The 8th IMPACCT: RWE Digital Summit
Returning as a fully virtual event for its 8th year, IMPACCT: RWE 2020 will once again support top innovators and leaders in the real-world evidence space with a comprehensive online forum dedicated to understanding and leveraging the expanding availability of real-world data across the drug development spectrum to transform patient outcomes.
This meeting will feature the most impactful collaborations in RWE yet, including medical affairs, patient engagement and clinical implantation experts, market access leaders, HEOR experts and payers.
Join companies such as AstraZeneca, Pfizer, Amgen, Bristol-Myers Squibb, MITRE and EMD Serono as they take you through key insights such as:
- RWE’s Global Opportunities & Emerging Markets
- RWE Pre & Post Launch Elements
- Strategic Vision for RWE Generation Across the Product Lifecycle
- Understanding the Global RWE Regulatory Landscape
Exclusive case studies, intriguing panels and a drive to overcome key challenges; leading experts are set to join us online at the 8th IMPACCT: RWE for a collaborative, open discussion to accelerate the meaningful implementation of real world evidence approaches to enhance clinical R&D outcomes, drive patient-centricity, and maximize the success of launch and commercialization activities.
Speaker Faculty Includes
Executive Director, Center for Observational Research & Data Sciences
Director, Value Measurement & Global Health Initiatives
Center for the Evaluation of Value and Risk in Health (CEVR)
Vice President, IBD Plexus
Crohn’s & Colitis Foundation
Hear What Previous Attendees Have To Say
"Very interesting networking and learning experience on the expanding growth of evidence generation and its use in
RWE Coordinator, Novartis
"The conference was an impactful couple of days to discuss opportunities and challenges
Director - Real World Evidence, Global Patient Outcomes & Real World Evidence, Eli Lilly & Co
"Great networking and free-flowing sharing of ideas,
challenges, and organizational structure between large
Director – Epidemiology, Alexion Pharmaceuticals